High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

ABSTRACT:

Introduction

We describe comorbidities and cardiovascular diseases (CVD) risk in patients with psoriasis prescribed apremilast in UK clinical practice. Such real-world data are currently sparse.

Methods

This observational, retrospective analysis of British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) included adults with plaque psoriasis first prescribed apremilast between October 2015 and March 2021. We evaluated patient comorbidities, 10-year CVD risk (Framingham risk score), time from psoriasis diagnosis, prior therapy, psoriasis severity and patient-reported quality of life (QoL) at first apremilast prescription or registry enrolment. Patient characteristics were also assessed by CVD risk and Fitzpatrick skin type.

Results

Of 265 e

SUBMITTER: Shams K 

PROVIDER: S-EPMC11971085 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature